The funding round was led by Archangels to support product development and US commercialisation.
Bioliberty is a Scottish technology firm that develops soft robotic gloves and digital therapy platforms designed to restore upper limb mobility for stroke patients.
Scottish technology firm Bioliberty has secured £2.2m in funding to advance its soft robotic glove and digital therapy platform aimed at upper limb stroke rehabilitation. The investment was led by business angel syndicate Archangels, with additional participation from Eos Advisory, Old College Capital and Hanna Capital SEZC.
The capital will support the company as it completes trial product development, finalises its software platform, and pursues regulatory approval in the US. Bioliberty intends to use the funds to prepare for early commercial engagement with rehabilitation clinics across the American market.
Co-founded in 2020, the Edinburgh-based firm produces the Lifeglov, a device that assists with hand strength recovery and provides remote management tools for occupational therapists. The recent injection of capital positions the business to scale its operations and expand its market reach.
Investor perspective
"Bioliberty has developed a highly effective solution for helping patients with hand weakness, with the potential to improve the quality of life for millions worldwide. We believe its technology has far-reaching benefits beyond this first application, providing the business with an excellent opportunity to grow quickly from its base here in Scotland. Archangels is excited to be supporting the team as they finalise what we hope will be the first of many products and start scaling up their sales activity."
Niki McKenzie
Joint Managing Director, Archangels
Use of funds
- 01Continue product development
- 02Accelerate go-to-market
Investors
Categories
About the company
Bioliberty
Bioliberty builds soft robotic gloves and digital therapy platforms for stroke rehabilitation.